Updated: 07:36 AM EDT DNAPrint genomics' Trace Genetics Laboratory Completes Analysis of 800-Year-Old DNA Samples From Mink Island for National Park Service
SARASOTA, FL -- (MARKET WIRE) -- 10/20/05 -- DNAPrint genomics, Inc. (OTC BB: DNAG) today announced that senior scientists from its Trace Genetics laboratory in Richmond, Calif., have completed analysis and reports on 800-year-old American Indian tooth samples from Mink Island, Alaska, for the National Park Service.
"Two of the samples had an identical DNA sequence, which suggests that the individuals could be siblings," said Dr. Ripan Malhi, Senior Research Director of Trace Genetics. "This is a sequence commonly found in many individuals from the Arctic and Subarctic, including the Chukchi, Siberian Inuits, Aleuts and Athapaskan groups."
Dr. Malhi noted that the sequence is also found in individuals of Apache and Nahua ancestry, suggesting that this lineage may have once been widely geographically dispersed throughout North America but is now restricted to the Arctic/Subarctic and Southwest/Mesoamerica, possibly as a result of European contact.
Mink Island is situated between the Aleutian Mountain Range and the Gulf of Alaska and, according to archaeological experts, has been occupied intermittently for the past 7,000 years. Its maritime inhabitants were limited to a narrow coastal corridor along the Gulf of Alaska.
In addition to providing clues about Mink Island's prehistory, the tests conducted by Trace Genetics provide an innovative way for archaeologists to manage the cultural resources found in U.S. National Parks. Retrieving mitochondria DNA (mtDNA) from ancient remains is extremely difficult to accomplish because it is usually degraded, resulting in a high likelihood of contamination due to handling of the bone or tooth during extraction in the laboratory. The Trace Genetics lab is one of a few that has the specialized facilities, experienced mtDNA researchers, and reliable protocols necessary to ensure accurate and reliable results.
The results of the Mink Island mtDNA analysis will be combined with additional anthropological data to help gain insight into the life patterns of these ancient people. Mitochondrial DNA is a useful tool for investigating the genetic identity of human remains because it is part of the mitochondrial genome and is found in high quantities outside of a cell's nucleus. Each cell contains approximately 700 mitochondria resulting in 100-1500 copies of the genome per cell in contrast to nuclear genes that have only two copies per cell. However, if analyzed incorrectly, the high copy number of mtDNA in a cell also make the analysis prone to false results due to contamination.
"It really is quite an accomplishment to be able to extract and analyze DNA from ancient tooth fragments," Dr. Malhi noted. "The Mink Island analysis validates that Trace Genetics has the reliable lab protocols necessary to analyze degraded DNA while retaining certainty of results."
posted
Yes, DNAG (DNAprint Denomics), seems like a bargain at .014 a share. I got in a little higher and am thinking of buying some more at these levels.
IP: Logged |
posted
DNAG seems like an interesting company. Wonder why it's trading so low. Anyone know anything about this company other than their basic profile?
IP: Logged |
posted
This stock is highly diluted; it made a lot noise but could not produce a rev. Please study the chart, you will find all investors are losers; only the MMs are making money.
IP: Logged |
posted
The chart to me looks like somebody is making money shorting this stock. And the company's profile still looks interesting to me. I'm not selling this one.
IP: Logged |
posted
Bought 10000 shares * .0258. After 20/1 r/s I now have 500 shares valued * 7.00. More dilution coming. I still like the co. Just finding a bottom is the problem. GL
IP: Logged |
posted
Updated: 07:15 AM EDT DNAPrint genomics Licenses Ritalin-Like Compounds Targeting Enhanced Treatment of Drug Addiction and Attention Deficit
SARASOTA, FL -- (MARKET WIRE) -- 10/25/05 -- DNAPrint genomics, Inc. (OTC BB: DNAG) today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine.
The licensed compounds are analogs of Ritalin(TM), a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the blood stream, thus reducing a patient's required daily dosage and the potential for drug abuse.
Methylphenidate was first introduced in the 1940s for patients suffering from narcolepsy, a sleeping disorder. Methylphenidate later was found to be useful in treating hyperactive children and adults with depression. One of the drawbacks for methylphenidate is the requirement for multiple daily doses because the drug reaches peak plasma concentrations in two hours and the half-life is only one to three hours, with 80% of the drug excreted during urination. Dosing starts out low and is gradually escalated to a maximum of 60 mg per day for children.
"Our methylphenidate analogs are designed to treat depression and hyperactivity while reducing the required dosing and mitigating significantly the potential for abuse. Additionally, the compounds have potential as treatments for cocaine abuse. In fact, the National Institute for Drug Abuse is advancing one of the compounds in its search for pharmaco-therapies for cocaine abuse," said Dr. Mark Froimowitz, the leading researcher from whom the technology was licensed. "These compounds were designed using molecular modeling and synthesized in a process developed by Dr. Charles Kelley. This research has come out of 25 years of work in the fields of drug addiction, Parkinson's disease and ADHD."
Drs. Froimowitz and Kelley have applied for patents for the newly licensed compounds.
Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, according to the consulting and research firm Decision Resources, Inc. "That's a significant opportunity for DNAPrint genomics and other drug developers," said Richard Gabriel, President and Chief Executive Officer of the Company. "The unique properties of these new compounds coupled with DNAPrint's expertise in determining the inherited gene characteristics of potential patients will enable us to target research on a drug for patients who respond positively to treatment, and hopefully, develop new compounds for those who might reject such a drug."
Dr. Froimowitz and DNAPrint genomics are also working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.
"One of the underlying goals is to utilize the newly licensed Froimowitz analogs to develop drugs for patients who do not respond to methylphenidate treatment at all," said Dr. Hector J. Gomez, DNAPrint's Chief Medical Officer. "We are all very excited about combining our ability to identify responder and non-responder patients using genetic ancestry and other clinical markers and target clinical development programs toward those patients."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
posted
With DNAG aquiring all these other companies, anybody here think that DNAG price will move upwards finally? OR is yet another surprise reverse split will be announced? Should of never got into PENNY stocks at all..... A life time of regret.....
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
posted
Remember the World Drug Discovery & Development Conference this company wil be attending 29/30 Nov. Conventions and conferences can many times give companys a nice little boost.
IP: Logged |
posted
Patience is a problem with me but I guess lots of it is required when wheelin and dealin with penny stocks. I've had DNAG for a couple of months now and still it's going nowhere. I'm still fairly new with these small cap stocks so alot of self education is needed. Making it big is a dream of mine and for many others but if you keep following your dreams, you'll eventually make it. (I hope) DWE
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
"The rich mystery of the human genome By Martha Slud CNNfn Staff Writer
Celera Genomics Group hopes to profit from sequencing the human genome by charging researchers a fee for access to the information
NEW YORK (CNNfn) -- The unraveling of the human genome has been dubbed the Holy Grail of the drug industry, a discovery that holds the secrets to how human beings live and die. And for Wall Street -- which is keeping a close eye on this scientific watershed -- the mysteries of the body's genetic makeup may hold the potential for great riches.
In the past year investors have become infatuated with genomics -- the study of the structure and function of genes -- sending shares in many young, yet-to-be-profitable biotechnology companies soaring.
The volatile sector has caught the attention of many investors who believe that genomics discoveries have the potential to revolutionize the way doctors diagnose disease and scientists find innovative new treatments for everything from cancer to Alzheimer's disease to depression.
Many investors who got their feet wet in the stock market through investments in another tumultuous sector -- the Internet -- are also attracted by the razzle-dazzle computer technology behind genomics.
Companies such as Celera Genomics Group, a Rockville, Maryland-based firm that says it has completed a "rough draft" of the human genome by processing reams of data through its supercomputers, more closely resemble high-tech firms in many ways than traditional biotech or drug companies.
Drug companies get in Major pharmaceutical companies meanwhile are quietly making their own investments in genomics. Drug makers, many of whom have launched their own genomics units, have entered strategic partnerships with gene-hunting companies such as Celera Genomics, Incyte Genomics Inc. and Millennium Pharmaceuticals to tap into their voluminous databases of genetic information.
For the drug industry, the hope is that once the genome is charted and read, scientists will have a greater understanding of mutations in genes that can cause illness. Then they can develop more potent drugs that are custom designed for a patient's individual genetic profile -- potentially opening the floodgates of drug discovery.
Drug makers eventually hope to get new medicines to market quicker through more effective clinical trials of medications that better target specific groups of the population based on similar gene types.
Research into the human genome "impacts everything we're doing in the entire discovery pipeline" of new medicines, said Nicholas Dracopoli, executive director of pharmacogenomics -- the application of genetic research to new drug development -- at Bristol Myers-Squibb, one of the largest U.S. drug makers.
Drug makers are betting genetic research will allow them to make medicines more effective by tailoring them to a patient's genetic profile
"The elucidation of the genome sequence will allow you to develop a much better molecular understanding of the cause of disease," he said. "If you understand the molecular basis of the disease, you will ultimately be able to develop much better pharmaceuticals." "
posted
AtHomeDad... Thanks for the article. Like you said, it doesn't mention DNAG but it was helpful. Still sounds like years and years of research and developement will be needed. I just hope in the meantime, DNAG won't surprise current shareholders with 5 more reverse splits in the future. DWE
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
posted
DNAPrint genomics CEO Richard Gabriel Featured in Interview in Wall Street Transcript's Biotechnology Issue
Thursday , November 17, 2005 07:00 ET
SARASOTA, FL, Nov 17, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) today announced that The Wall Street Transcript has published a biotechnology issue which features a comprehensive interview with Richard Gabriel, the Company's President and Chief Executive Officer.
During the interview Mr. Gabriel traces how DNAPrint genomics has evolved into a company focused on three areas: pharmacogenomics and the development of personalized test/drug combinations called theranostics; genealogy, which is basically a consumer ancestry product, and forensics for law enforcement. "Pharmacogenomics is the Company's biggest market opportunity, and we've focused on developing pharmaceutical applications for our products and services," he stated.
The interview is available the Company's website at www.dnaprint.com and can be accessed by subscribers on the Transcript's Web site (www.twst.com).
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2005 Market Wire, All rights reserved.
IP: Logged |
quote:Originally posted by DWE: AtHomeDad... Thanks for the article. Like you said, it doesn't mention DNAG but it was helpful. Still sounds like years and years of research and developement will be needed. I just hope in the meantime, DNAG won't surprise current shareholders with 5 more reverse splits in the future. DWE
yeah, i got a little scar from at least one of those. like they say once bitten twice shy. glta, and have some fun.
-------------------- Time will give you what you want!
IP: Logged |
posted
DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum
Friday , November 18, 2005 07:00 ET
SARASOTA, FL, Nov 18, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that Dr. Barbara Handelin, the Company's General Manager of Computational Biology, will be presenting before The Wall Street Analyst Forum Institutional Investor Conference at The Roosevelt Hotel, Madison Avenue at 45th Street, in New York City at 11:00 a.m. Eastern time on Wednesday, November 30.
During the 40-minute presentation, which can also be heard via a live webcast on the Company's website at www.dnaprint.com or at http://www.investorcalendar.com/CEPage.asp?ID=97888, Dr. Handelin will provide an overview of the Company and discuss its goals and outlook for the future. The webcast will also be archived. To register for the conference, please visit www.analyst-conference.com or contact The Wall Street Group, Inc. at 212-888-4848.
The Wall Street Analyst Forum brings together financial analysts and portfolio managers who are interested in learning about the companies participating in the investor conference and provides them the opportunity to personally meet company personnel and learn more about the company.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
posted
DNAG sounds to be promising and I hope they'll stay that way from the start of 2006 to the end. Not buying or selling either, although, I wish I would of sold that day when it was way up. Forgot which day and what price it was at but it was UP!
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
posted
Set your goal at 0.0218, it might get hit when next pr comes out. I got out this way a few weeks ago. Hey, DWE, we were in the same boats of MRKL and DNAG. I feel I am a free man after getting out of them. I hope you will set your self free soon. Don't mix the technology with the management. DNAG magnagement is taking advantage of the scitific venture to trap investors. I consider my loss in the MRKL a tuition for learning stock trading. Since then, I have a string of good luck in getting hit.
IP: Logged |
posted
Thanks JimSC. I have a feeling that I'll have better luck with DNAG than with MRKL. MRKL has been a nightmare since buying at 3.4 cents a few months ago just to see it drop down to the low twos. I've only been doing this penny stuff since Sept and I've got a LONG way to go.
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
posted
Khandaker Partners Initiates Research on DNAPrint genomics, Inc.
Monday , November 21, 2005 07:00 ET
SARASOTA, FL, Nov 21, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that Khandaker Partners, an independent research and advisory firm specializing in small cap and emerging growth companies, has prepared a research report on the Company and its technology.
Included in the report is a comprehensive interview with Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer, and Richard Gabriel, President and Chief Executive Officer, who lay out their vision for the DNAPrint genomics' future.
Copies of the report can be obtained by emailing rripatti*khandaker.com.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com), through its DNAPrint Pharmaceutics, Inc., wholly owned subsidiary, is a developer of genomics-based products and services focused on drug development, computational biology and pharmacogenomic diagnostic tests. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint also develops and markets products for the law enforcement forensics and consumer markets that include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint genomics, Inc.
Copyright 2005 Market Wire, All rights reserved.
IP: Logged |
posted
I'm hoping that DNAG has a good day everyday this week. When DNAG hits higher prices like this, it usually goes down the very next day. I hope that's not the case for this company. My hats off to DNAG. Let's go baby!!!
-------------------- "NEVER UNDERESTIMATE THE POWER OF THE U.S./CHINA CONNECTION"
posted
Hey, Dwe, it hit 0.024 today. Take your profit and go. Did you place a sale order as I suggested a few days ago? Happy Holidays. JimSC
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
